Czech National Bank Buys 2,380 Shares of Catalent, Inc. (NYSE:CTLT)

Czech National Bank boosted its stake in shares of Catalent, Inc. (NYSE:CTLT) by 6.9% during the third quarter, Holdings Channel.com reports. The firm owned 36,867 shares of the company’s stock after purchasing an additional 2,380 shares during the quarter. Czech National Bank’s holdings in Catalent were worth $2,233,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its holdings in Catalent by 1.7% in the second quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company’s stock worth $619,000 after acquiring an additional 185 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after acquiring an additional 212 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in Catalent by 1.4% in the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,238 shares of the company’s stock worth $1,082,000 after acquiring an additional 257 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its holdings in Catalent by 3.8% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 7,688 shares of the company’s stock worth $432,000 after acquiring an additional 278 shares in the last quarter. Finally, Longfellow Investment Management Co. LLC boosted its holdings in Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after acquiring an additional 305 shares in the last quarter.

Catalent Stock Down 0.4 %

Shares of CTLT stock opened at $60.45 on Friday. The stock has a 50 day moving average of $60.03 and a 200 day moving average of $57.65. The company has a current ratio of 2.52, a quick ratio of 1.96 and a debt-to-equity ratio of 1.35. The stock has a market cap of $10.94 billion, a P/E ratio of -9.91, a P/E/G ratio of 2.14 and a beta of 1.15. Catalent, Inc. has a twelve month low of $31.80 and a twelve month high of $61.20.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Thursday, August 29th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.13. The company had revenue of $1.30 billion during the quarter, compared to analysts’ expectations of $1.23 billion. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. As a group, sell-side analysts expect that Catalent, Inc. will post 0.95 EPS for the current year.

Analyst Ratings Changes

Several brokerages have weighed in on CTLT. William Blair reissued a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. StockNews.com began coverage on Catalent in a research note on Saturday. They issued a “hold” rating for the company. Robert W. Baird restated a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. Barclays raised their price objective on Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research note on Friday, June 28th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a research note on Thursday, July 11th. Nine analysts have rated the stock with a hold rating, According to data from MarketBeat.com, Catalent currently has a consensus rating of “Hold” and a consensus price target of $59.83.

Insider Activity

In other news, CEO Alessandro Maselli sold 9,088 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $58.76, for a total value of $534,010.88. Following the completion of the sale, the chief executive officer now directly owns 177,521 shares in the company, valued at $10,431,133.96. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now directly owns 36,304 shares of the company’s stock, valued at $2,177,150.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Alessandro Maselli sold 9,088 shares of Catalent stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $58.76, for a total value of $534,010.88. Following the completion of the sale, the chief executive officer now directly owns 177,521 shares in the company, valued at $10,431,133.96. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 12,410 shares of company stock worth $732,680 over the last three months. 0.31% of the stock is currently owned by corporate insiders.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.